What if the targets I identify have been reported in the past?

If AI-driven identification work funded through this programme uncovers strong new evidence for a previously known therapeutic target, it may be eligible for applications into the next phase. We will consider such targets if they have not been previously validated and are not part of any known therapeutic development efforts. What’s important is whether your findings highlight the target as a promising and underexplored opportunity for therapy by clearly strengthening the case for its role in the biological mechanisms that drive ALS.